TEVA PHARMACEUTICALS USA, INC. - 8511784063!ADENOVIRUS TYPE 4 A
Key Details
Description
8511784063!ADENOVIRUS TYPE 4 A
Context & Analysis
On Dec 1, 2025, Department of Defense obligated $1,981,883.16 to TEVA PHARMACEUTICALS USA, INC. for 8511784063!adenovirus type 4 a. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: not competed. Performance is located in PARSIPPANY, NJ. This award is one of several similar procurements from Department of Defense under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
LUTATHERA AND PLUVICTO
NOVARTIS PHARMACEUTICALS CORPORATION
$3.2M
8511784064!ADENOVIRUS TYPE 4 A
TEVA PHARMACEUTICALS USA, INC.
$1.3M
4569692252!RSDL
CANADIAN COMMERCIAL CORPORATION
$747,796
8511784112!ADENOVIRUS TYPE 4 A
TEVA PHARMACEUTICALS USA, INC.
$660,627.72
8511784111!ADENOVIRUS TYPE 4 A
TEVA PHARMACEUTICALS USA, INC.
$660,627.72
Stay Updated
Get notified about new opportunities matching your interests.